Lymphoplasmacytic lymphoma classification: Difference between revisions

	Lymphoplasmacytic lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Lymphoplasmacytic Lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Lymphoplasmacytic lymphoma classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Lymphoplasmacytic lymphoma classification
CDC on Lymphoplasmacytic lymphoma classification
Lymphoplasmacytic lymphoma classification in the news
Blogs on Lymphoplasmacytic lymphoma classification
Directions to Hospitals Treating Psoriasis
Risk calculators and risk factors for Lymphoplasmacytic lymphoma classification

VisualWikitext

Revision as of 15:06, 12 February 2019

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

There is no established system for the classification of [disease name].

OR

[Disease name] may be classified according to [classification method] into [number] subtypes/groups: [group1], [group2], [group3], and [group4].

OR

[Disease name] may be classified into [large number > 6] subtypes based on [classification method 1], [classification method 2], and [classification method 3]. [Disease name] may be classified into several subtypes based on [classification method 1], [classification method 2], and [classification method 3].

OR

Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.

OR

If the staging system involves specific and characteristic findings and features: According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].

OR

The staging of [malignancy name] is based on the [staging system].

OR

There is no established system for the staging of [malignancy name].

Classification

There is no established system for the classification of Waldenström's macroglobulinemia. However, according to a devised criteria based upon patient's symptoms, it can be classified into:^[1]

Symptomatic Waldenstrom macroglobulinemia.
Asymptomatic/Smoldering Waldenstrom macroglobulinemia (SWM).^[2]

**Classification of WM and Related Disorders**
Criteria	Symptomatic WM	Asymptomatic WM	IgM-Related Disorders	MGUS
IgM monoclonal protein	+	+	+	+
Bone marrow infiltration	+	+	-	-
Symptoms attributable to IgM	+	-	+	-
Symptoms attributable to tumor infiltration	+	-	-	-

References

↑ Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.
↑ Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M; et al. (2003). "Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia". Semin Oncol. 30 (2): 116–20. doi:10.1053/sonc.2003.50038. PMID 12720119.

Template:WH Template:WS

[pmid15735132-1] Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP (2005). "Diagnosis and management of Waldenstrom's macroglobulinemia". J Clin Oncol. 23 (7): 1564–77. doi:10.1200/JCO.2005.03.144. PMID 15735132.

[pmid12720119-2] Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M; et al. (2003). "Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia". Semin Oncol. 30 (2): 116–20. doi:10.1053/sonc.2003.50038. PMID 12720119.

[1]

[2]

@@ Line 33: / Line 33: @@
 ==Classification==
+There is no established system for the classification of Waldenström's macroglobulinemia. However, according to a devised criteria based upon patient's symptoms, it can be classified into:<ref name="pmid15735132">{{cite journal| author=Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP| title=Diagnosis and management of Waldenstrom's macroglobulinemia. | journal=J Clin Oncol | year= 2005 | volume= 23 | issue= 7 | pages= 1564-77 | pmid=15735132 | doi=10.1200/JCO.2005.03.144 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15735132  }} </ref>
-There is no established system for the classification of [disease name].
+*Symptomatic Waldenstrom macroglobulinemia.
+*Asymptomatic/Smoldering Waldenstrom macroglobulinemia (SWM).<ref name="pmid12720119">{{cite journal| author=Kyle RA, Treon SP, Alexanian R, Barlogie B, Björkholm M, Dhodapkar M et al.| title=Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. | journal=Semin Oncol | year= 2003 | volume= 30 | issue= 2 | pages= 116-20 | pmid=12720119 | doi=10.1053/sonc.2003.50038 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12720119  }} </ref>
-OR
+{| class="wikitable"
+|+ '''Classification of WM and Related Disorders'''
-[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Criteria
-*[Group1]
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Symptomatic WM
-*[Group2]
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |Asymptomatic WM
-*[Group3]
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |IgM-Related Disorders
-*[Group4]
+! style="background:#4479BA; color: #FFFFFF;" align="center" + |MGUS
+|-
-OR
+| style="background:#DCDCDC;" align="center" + |IgM monoclonal protein
+| style="background:#F5F5F5;" align="center" + |+
-[Disease name] may be classified into [large number > 6] subtypes based on:
+| style="background:#F5F5F5;" align="center" + |+
-*[Classification method 1]
+| style="background:#F5F5F5;" align="center" + |+
-*[Classification method 2]
+| style="background:#F5F5F5;" align="center" + |+
-*[Classification method 3]
+|-
+| style="background:#DCDCDC;" align="center" + |Bone marrow infiltration
-[Disease name] may be classified into several subtypes based on:
+| style="background:#F5F5F5;" align="center" + |+
-*[Classification method 1]
+| style="background:#F5F5F5;" align="center" + |+
-*[Classification method 2]
+| style="background:#F5F5F5;" align="center" + |-
-*[Classification method 3]
+| style="background:#F5F5F5;" align="center" + |-
+|-
-OR
+| style="background:#DCDCDC;" align="center" + |Symptoms attributable to IgM
+| style="background:#F5F5F5;" align="center" + |+
-Based on the duration of symptoms, [disease name] may be classified as either acute or chronic.
+| style="background:#F5F5F5;" align="center" + |-
+| style="background:#F5F5F5;" align="center" + |+
-OR
+| style="background:#F5F5F5;" align="center" + |-
+|-
-'''If the staging system involves specific and characteristic findings and features:'''
+| style="background:#DCDCDC;" align="center" + |Symptoms attributable to tumor infiltration
+| style="background:#F5F5F5;" align="center" + |+
-According to the [staging system + reference], there are [number] stages of [malignancy name] based on the [finding1], [finding2], and [finding3]. Each stage is assigned a [letter/number1] and a [letter/number2] that designate the [feature1] and [feature2].
+| style="background:#F5F5F5;" align="center" + |-
+| style="background:#F5F5F5;" align="center" + |-
-OR
+| style="background:#F5F5F5;" align="center" + |-
+|}
-The staging of [malignancy name] is based on the [staging system].
-OR
-There is no established system for the staging of [malignancy name].
 ==References==

Lymphoplasmacytic lymphoma classification: Difference between revisions

Revision as of 15:06, 12 February 2019

Overview

Classification

References

Navigation menu